TY - JOUR ID - 298391 TI - Humoral and Interferon-γ Immune Response to DNA Vaccine Encoding The surface Glycoprotein B of Infectious Laryngotracheitis Virus JO - Egyptian Journal of Veterinary Sciences JA - EJVS LA - en SN - 1110-0222 AU - gamal, Maha Aboelnaga AU - Soliman, Yousef AD - biotechnology department,1Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), Agricultural Research Center {ARC}, Cairo, Egypt AD - Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), Agricultural Research Center {ARC}, Cairo.) Y1 - 2023 PY - 2023 VL - 54 IS - 4 SP - 631 EP - 642 KW - Infectious laryngotracheitis- virus (ILTV) KW - DNA vaccine KW - glycoprotein B gene (gpB) DO - 10.21608/ejvs.2023.204396.1483 N2 - DNA vaccines continue to be a suitable safe and potent alternative particularly for controlling the infection with pathogens that rely on the cell-mediated type of immune response and for the ability to eliminate viral shedding. Infectious laryngotracheitis virus causes a contagious respiratory disease with a considerable economic impact. DNA vaccine was developed coding for the surface glycoprotein B gene (gpB) from locally isolated strain. The developed vaccine (pcDEST40-gpB) could elicit potent antibody titers positively correlated with the commercially available live TC-propagated ILT vaccine. Cell-mediated immune response (as measured by quantitation of the IFN-γ gene transcript ), revealed that both DNA vaccine and live vaccine initiate a powerful fold change in IFN-γ till the 15 days post-vaccination, however, the use of booster dose of DNA vaccine resulted in an abrupt increase in the level of IFN-γ transcript which was significantly higher than that of the live vaccine by day 7 post-challenge and onward. DNA vaccine but not the live vaccine could eliminate the shedding of the virus post-challenge. UR - https://ejvs.journals.ekb.eg/article_298391.html L1 - https://ejvs.journals.ekb.eg/article_298391_3da37b54c53d3949e805f7a2cda4a8bf.pdf ER -